AI in Point-of-Care Imaging for Clinical Decision Support: Systematic Review of Diagnostic Accuracy, Task-Shifting, and Explainability.

AI in Point-of-Care Imaging for Clinical Decision Support: Systematic Review of Diagnostic Accuracy, Task-Shifting, and Explainability.

Publication date: Apr 27, 2026

Artificial intelligence (AI) integrated with point-of-care imaging is a promising approach to expand access in settings with limited specialist availability. However, no systematic review has comprehensively evaluated AI-assisted clinical decision support across multiple point-of-care imaging modalities, assessed explainability implementation, or quantified clinical impact evidence gaps. We aim to systematically evaluate and synthesize evidence on AI-based clinical decision support systems using point-of-care imaging. We searched PubMed, Scopus, IEEE Xplore, and Web of Science (January 2018 to November 2025). We included research studies evaluating AI or machine learning systems applied to point-of-care-capable imaging modalities in clinical settings with clinical decision support outputs. Two reviewers independently screened studies, extracted data across 15 domains, and assessed methodological quality using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2). Proposed frameworks were developed to evaluate explainability implementation and clinical impact evidence. Narrative synthesis was performed due to substantial data heterogeneity. Of 2113 records identified, 20 studies met inclusion criteria, encompassing approximately 78,000 patients across 15 countries. Studies evaluated tuberculosis (n=5), breast cancer (n=3), deep vein thrombosis (DVT) (n=2), and 9 other conditions using ultrasound (7/20, 35%), chest x-ray (5/20, 25%), photography-based and colposcopic imaging (3/20, 15%), fundus photography (2/20, 10%), microscopy (2/20, 10%), and dermoscopy (1/20, 5%). Median sensitivity was 93. 6% (IQR 87%-98%), and median specificity was 90. 6% (IQR 74. 5%-96. 7%). Task-shifting was demonstrated in 65% (13/20) of studies, with nonspecialists achieving specialist-level performance after a median of 1 hour of training (range 30 minutes to 6 months; n=6 studies reporting specific durations). The explainable artificial intelligence (XAI) implementation cascade revealed critical gaps: 75% (15/20) of studies did not mention explainability, 10% (2/20) provided explanations to users, and none evaluated whether clinicians understood explanations or whether XAI influenced decisions. The clinical impact pyramid showed 15% (3/20) of studies reported technical accuracy only, 65% (13/20) reported process outcomes, 20% (4/20) documented clinical actions, and none measured patient outcomes. Methodological quality was concerning, as 70% (14/20) of studies were at high or very high risk of bias, with verification bias (14/20, 70%) and selection bias (10/20, 50%) being the most common. The overall certainty of evidence was very low-GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) ⊕◯◯◯, primarily due to risk of bias, heterogeneity, and imprecision. AI-assisted point-of-care imaging demonstrates promising diagnostic accuracy and enables meaningful task-shifting with minimal training requirements. However, critical evidence gaps remain, including absent patient outcome measurement, inadequate explainability evaluation, regulatory misalignment, and lack of cross-context validation despite claims of global applicability. Addressing these gaps requires implementation research with patient-outcome end points, rigorous XAI evaluation, and multicontext validation before widespread adoption. Limitations include restriction to English-language publications, gray literature exclusion, and heterogeneity precluding meta-analysis.

Open Access PDF

Concepts Keywords
Learning AI
Nonspecialists artificial intelligence
Tuberculosis CDSS
Ultrasound diagnostic imaging
explainability
explainable AI
machine learning
mobile phone
POC
point-of-care systems
task shifting
XAI

Semantics

Type Source Name
disease MESH deep vein thrombosis
pathway KEGG Breast cancer
disease MESH breast cancer
pathway KEGG Tuberculosis
disease MESH tuberculosis
drug DRUGBANK Methionine
disease MESH included
disease MESH plan
drug DRUGBANK Factor IX Complex (Human)
disease MESH PCC
disease MESH emergency
drug DRUGBANK Aspartame
disease MESH image
disease MESH aids
disease MESH tics
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Coenzyme M
disease MESH CDS
disease MESH Pressure ulcers
disease MESH Diabetic retinopathy
disease MESH Hip dysplasia
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH Helminthiases
disease MESH Malaria
pathway KEGG Malaria
drug DRUGBANK Cefradine
disease MESH cED
disease MESH LICs
disease MESH cervical cancer
disease MESH developmental hip dysplasia
disease MESH parasitic infections
disease MESH EDa
drug DRUGBANK Etoperidone
disease MESH GPs
drug DRUGBANK Acetic acid
disease MESH SSD
drug DRUGBANK Flunarizine
disease MESH DRd

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *